Projet TRIM-NET (Horizon 2020, appel à projets 2018)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

The TRIM-NET innovative training programme will provide Early-Stage Researchers with the skills to identify novel therapeutic targets and develop the strategies to validate them in preclinical studies. Integrating complementary expertise and multidisciplinary approaches TRIM-NET aims to address this goal, focussing on the Tripartite motif (TRIM) family of Ubiquitin E3 ligases, which plays an important role in many physiological processes. The importance of the role of TRIM proteins in these processes is underpinned by their recognised involvement in many disease processes such as cancer, neurodegeneration and rare genetic diseases. As such, they are excellent targets for therapeutic manipulation. The TRIM-NET consortium created a critical mass with complementary and interdisciplinary expertise, from Life Science to Chemistry, around this family of proteins to identify and exploit common targeting strategies for translational applications. The consortium is designed to train a cohort of researchers in skills and expertise essential for biomedical research in the era of personalised medicine, focussing on determining how: i) TRIM proteins contribute to disease; ii) to develop strategies to modulate TRIM proteins activity; iii) to design high throughput screening assays for drug discovery. The training programme comprises 7 highly integrated work packages: 4 scientific and 3 dedicated to training, dissemination and management. The proposal consists of 12 individual research projects that will form the basis of the research training aspects for the ESR recruited to the programme. As the scientific work packages are highly integrated, recruited ESRs will avail of techniques and training opportunities, including secondments, across the work packages. Through a unique international partnership between academic and non-academic partners the TRIM-NET training programme will provide ESRs with skills that are essential for future biomedical research in industry and academia.

Mots clés : ubiquitination, e3 ligases, drug discovery, peptide chemistry, biomaterials synthesis

Participants :
- Karlsruhe Institute of Technology (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- PharmaTrain Federation (Belgique) — Partner, organization partner, Autres, subvention : 0.0 €
- University of Trieste (Italie) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 522999.36 €
- Spanish National Research Council (Espagne) — Partner, beneficiary, Recherche, subvention : 250904.88 €
- Istituti di Ricovero e Cura a Carattere Scientifico (Italie) — Partner, beneficiary, Recherche, subvention : 261499.68 €
- Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (France) — Partner, beneficiary, Recherche, subvention : 274802.04 €
- Crown bioscience netherlands bv (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Dundee (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 303172.56 €
- Centre national de la recherche scientifique (France) — Partner, beneficiary, Recherche, subvention : 274802.04 €
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 531239.76 €
- Consorzio per l'AREA di Ricerca Scientifica e Tecnologica di Trieste (Italie) — Partner, organization partner, Recherche, subvention : 0.0 €
- Leiden University Medical Center (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 531239.76 €
- Labcyte ltd (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ubiquigent ltd (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €